1. Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study. (February 2017) Authors: Necchi, A.; Bellmunt, J.; De Wit, R.; Vaughn, D.; Fradet, Y.; Lee, J.L.; Fong, L.; Vogelzang, N.; Climent, M.; Petrylak, D.; Choueiri, T.; Gerritsen, W.; Gurney, H.; Quinn, D.; Culine, S.; Sternberg, C.; Mai, Y.; Puhlmann, M.; Perini, R.; Bajorin, D. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗